Evidence map›Paper›PMID 39983270›Full record

ReviewDNA repair2025

Pathological modulation of genome maintenance by cancer/testes antigens (CTAs).

Cyrus Vaziri, Karly Forker, Xingyuan Zhang, Di Wu, Pei Zhou, Jessica L Bowser

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in DNA repair, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Cyrus VaziriDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: cyrus_vaziri@med.unc.edu.
Karly ForkerDepartment of Biochemistry, Duke University School of Medicine, Durham, NC 27710, USA.
Xingyuan ZhangDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC 27710, USA.
Di WuLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Biostatistics, University of North Carolina, Chapel Hill, NC 27599, USA.
Pei ZhouDepartment of Biochemistry, Duke University School of Medicine, Durham, NC 27710, USA.
Jessica L BowserDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: jlbowser@email.unc.edu.

Funding

Pathological Reprogramming of DNA Damage Signaling in Neoplastic CellsR01ES029079 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Kenneth Hugh Pearce, Cyrus Vaziri · 2021 to 2023
$1.4M
A Novel Carcinogen-Induced Cell Cycle CheckpointR01ES009558 · BOSTON UNIVERSITY MEDICAL CAMPUS · 2002 to 2005
$1.3M
Inhibiting Rev1-mediated translesion DNA synthesis for cancer therapyR01CA279034 · DUKE UNIVERSITY · 2025 to 2025
$522k
Defining Mechanisms of Pathological Trans-Lesion Synthesis During CarcinogenesisR01CA215347 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Cyrus Vaziri, SCOTT E WILLIAMS · 2022 to 2022
$508k
NCI NIH HHS R01 CA215347NCI NIH HHS R01 CA229530NCI NIH HHS R01 CA279034NIEHS NIH HHS R01 ES009558NIEHS NIH HHS R01 ES029079
6 · The paper itself

Abstract

The Cancer Testis Antigens (CTAs) are a group of germ cell proteins that are absent from normal somatic cells yet aberrantly expressed in many cancer cells. When mis-expressed in cancer cells, many CTAs promote tumorigenic characteristics including genome instability, DNA damage tolerance and therapy resistance. Here we highlight some of the CTAs for which their roles in genome maintenance in cancer cells are well established. We consider three broad CTA categories: (1) Melanoma Antigens (MAGEs) (2) Mitotic CTAs and (3) CTAs with roles in meiotic homologous recombination. Many cancer cells rely on CTAs to tolerate intrinsic and therapy-induced genotoxic stress. Therefore, CTAs represent molecular vulnerabilities of cancer cells and may provide opportunities for therapy. Owing to their high-level expression in tumors and absence from normal somatic cells, CTA-directed therapies could have a high level of specificity and would likely be devoid of side-effect toxicity.

Indexed as

Antigens, NeoplasmGenomic InstabilityNeoplasmsAnimalsDNA DamageDNA RepairHomologous RecombinationHumansMaleTestisAntigens, NeoplasmCancer testes antigens (CTAs)Cancer therapyDNA damageDNA repairGenome instabilityGenome maintenance

Identifiers

PMID39983270
PMCPMC11923853

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.